Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Jerry M. Tolson"'
Autor:
Hendrik-Tobias Arkenau, Johann S. de Bono, Li Yan, Jeffrey R. Infante, Yung-Jue Bang, Sunil Sharma, Joseph P. Eder, Hyun Cheol Chung, Sun Young Rha, Jerry M. Tolson, Rakesh Kumar, Monica Motwani, Jiuhua Wu, Shanker Kalyana-Sundaram, Deborah A. Smith, M. Phillip DeYoung, Shaun Decordova, Karen Swales, Sae-Won Han, Howard A. Burris, Charlotte Lemech, Gopinath Ganji, Joaquin Mateo
Supplementary Table 7: Next-generation sequencing of tumor biopsy samples (see separate Excel file) Supplementary Table 8: Copy number variations for patients with tumor biopsy samples available (see separate Excel file) Supplementary Table 9: Summar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dfa50e068207514fe340c2597b87452
https://doi.org/10.1158/1078-0432.22468446
https://doi.org/10.1158/1078-0432.22468446
Autor:
Hendrik-Tobias Arkenau, Johann S. de Bono, Li Yan, Jeffrey R. Infante, Yung-Jue Bang, Sunil Sharma, Joseph P. Eder, Hyun Cheol Chung, Sun Young Rha, Jerry M. Tolson, Rakesh Kumar, Monica Motwani, Jiuhua Wu, Shanker Kalyana-Sundaram, Deborah A. Smith, M. Phillip DeYoung, Shaun Decordova, Karen Swales, Sae-Won Han, Howard A. Burris, Charlotte Lemech, Gopinath Ganji, Joaquin Mateo
Supplementary Figure 1: Study design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a39f1e4acd2ba5c60c4b80f85a5a4dc7
https://doi.org/10.1158/1078-0432.22468458.v1
https://doi.org/10.1158/1078-0432.22468458.v1
Autor:
Hendrik-Tobias Arkenau, Johann S. de Bono, Li Yan, Jeffrey R. Infante, Yung-Jue Bang, Sunil Sharma, Joseph P. Eder, Hyun Cheol Chung, Sun Young Rha, Jerry M. Tolson, Rakesh Kumar, Monica Motwani, Jiuhua Wu, Shanker Kalyana-Sundaram, Deborah A. Smith, M. Phillip DeYoung, Shaun Decordova, Karen Swales, Sae-Won Han, Howard A. Burris, Charlotte Lemech, Gopinath Ganji, Joaquin Mateo
Supplementary Figure 3: Glucose and insulin levels after treatment with GSK2636771 in fasted mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::369716f0008acebd72ad590670fe3760
https://doi.org/10.1158/1078-0432.22468452.v1
https://doi.org/10.1158/1078-0432.22468452.v1
Autor:
Hendrik-Tobias Arkenau, Johann S. de Bono, Li Yan, Jeffrey R. Infante, Yung-Jue Bang, Sunil Sharma, Joseph P. Eder, Hyun Cheol Chung, Sun Young Rha, Jerry M. Tolson, Rakesh Kumar, Monica Motwani, Jiuhua Wu, Shanker Kalyana-Sundaram, Deborah A. Smith, M. Phillip DeYoung, Shaun Decordova, Karen Swales, Sae-Won Han, Howard A. Burris, Charlotte Lemech, Gopinath Ganji, Joaquin Mateo
Background: The PI3K/protein kinase B (AKT) pathway is commonly activated in several tumor types. Selective targeting of p110β could result in successful pathway inhibition while avoiding the on- and off-target effects of pan-PI3K inhibitors. GSK263
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e88911e3f343071194a98323816102ae
https://doi.org/10.1158/1078-0432.c.6526947.v1
https://doi.org/10.1158/1078-0432.c.6526947.v1
Autor:
Hendrik-Tobias Arkenau, Johann S. de Bono, Li Yan, Jeffrey R. Infante, Yung-Jue Bang, Sunil Sharma, Joseph P. Eder, Hyun Cheol Chung, Sun Young Rha, Jerry M. Tolson, Rakesh Kumar, Monica Motwani, Jiuhua Wu, Shanker Kalyana-Sundaram, Deborah A. Smith, M. Phillip DeYoung, Shaun Decordova, Karen Swales, Sae-Won Han, Howard A. Burris, Charlotte Lemech, Gopinath Ganji, Joaquin Mateo
Supplementary Table 1: 3 + 3 dose escalation guidelines Supplementary Table 2: Customized sequencing panel Supplementary Table 3: Summary of AEs occurring in >20% of all patients, treatment-related AEs and SAEs Supplementary Table 4: PK parameters fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b2914c781168e583ece8cd2996b4a24
https://doi.org/10.1158/1078-0432.22468461
https://doi.org/10.1158/1078-0432.22468461
Autor:
Hendrik-Tobias Arkenau, Johann S. de Bono, Li Yan, Jeffrey R. Infante, Yung-Jue Bang, Sunil Sharma, Joseph P. Eder, Hyun Cheol Chung, Sun Young Rha, Jerry M. Tolson, Rakesh Kumar, Monica Motwani, Jiuhua Wu, Shanker Kalyana-Sundaram, Deborah A. Smith, M. Phillip DeYoung, Shaun Decordova, Karen Swales, Sae-Won Han, Howard A. Burris, Charlotte Lemech, Gopinath Ganji, Joaquin Mateo
Supplementary Figure 2: LNCAP and DU-145 prostate cancer cells were treated with 1 or 10 μM GSK2636771 for up to 48 hours and probed with the indicated antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a3127a7afbf6dc0a774636c87ed83be
https://doi.org/10.1158/1078-0432.22468455
https://doi.org/10.1158/1078-0432.22468455
Autor:
Hendrik-Tobias Arkenau, Johann S. de Bono, Li Yan, Jeffrey R. Infante, Yung-Jue Bang, Sunil Sharma, Joseph P. Eder, Hyun Cheol Chung, Sun Young Rha, Jerry M. Tolson, Rakesh Kumar, Monica Motwani, Jiuhua Wu, Shanker Kalyana-Sundaram, Deborah A. Smith, M. Phillip DeYoung, Shaun Decordova, Karen Swales, Sae-Won Han, Howard A. Burris, Charlotte Lemech, Gopinath Ganji, Joaquin Mateo
Supplementary Figure 4: Investigation of the p.L1049R mutation identified in a patient with castration-resistant prostate cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::392ff8d29623d05c386df7a5131a0b6e
https://doi.org/10.1158/1078-0432.22468449
https://doi.org/10.1158/1078-0432.22468449
Autor:
Hendrik-Tobias Arkenau, Li Yan, Jolly Mazumdar, Noelia Nebot, K. Auger, Jianping Zhang, Ruth Plummer, Sarah P. Blagden, Alastair Greystoke, Jean-Charles Soria, Jerry M. Tolson, Ivana Rizzuto, Debra Rogan, Gabriel Mak, Ronald A. Fleming, Anas Gazzah
Publikováno v:
British Journal of Cancer
Background Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy. Methods This dose-finding phase Ib study (adaptive 3 + 3 design) determined the maximum tolerated dose (MTD) of trametinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff990b1bbc281654596e70f649a4e9a4
https://doi.org/10.1038/s41416-019-0452-3
https://doi.org/10.1038/s41416-019-0452-3
Autor:
Christophe Plisson, Kurt R. Auger, Matthew Williams, Yvonne Lewis, Sarah P. Blagden, Azeem Saleem, Jerry M. Tolson, Ronald A. Fleming, Li Yan, Nicholas F Brown, Laurie Lenox, Hendrik-Tobias Arkenau, Rajendra P. Singh, Graham E. Searle, Paul Mulholland, Jianping Zhang, David Cox
Publikováno v:
Neuro-Oncology. 20:1634-1642
Background GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor. Preclinical studies demonstrate growth inhibition in glioblastoma cell lines. However, rodent studies indicate limited blood–brain barrier (BBB) penetration. In this expan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31dbaea36402f534744fadb8cdd1f456
https://doi.org/10.1093/neuonc/noy078
https://doi.org/10.1093/neuonc/noy078
Autor:
Amit, Bar-Or, Richard A, Grove, Jerry M, Tolson, Frederick J, Derosier, Monica C, Lopez, Sarah T, Kavanagh, Aaron E, Miller
Publikováno v:
Neurology. 92(11)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b75d32f23c4af191b7acd09819dfa50e
https://pubmed.ncbi.nlm.nih.gov/30858244
https://pubmed.ncbi.nlm.nih.gov/30858244